Sep 27, 2021 / 06:00PM GMT
Alethia Young - Cantor Fitzgerald & Co. - Analyst
Hey, everybody. It's Alethia Young; I cover large cap, small/mid cap biotech here at Cantor. Very happy to have Akebia with us. And I have John Butler who is the CEO. We will be doing a fireside chat for the next 30 minutes. I almost said 30 seconds, which would be quite brief, but the next 30 minutes. But I did want to start with John just kind of framing some of the accomplishments of vadadustat over the past 12 months because there have been many. So John, please go ahead.
John Butler - Akebia Therapeutics, Inc. - President & CEO
Thanks, Alethia. Thanks so much for the invitation here. So it has been a busy year for us at Akebia.
Vadadustat, as you referenced, is our kind of the key value driver, I think, for the Company. It is hypoxia--inducible factor prolyl hydroxylase inhibitor. It's under review by the FDA now for the anemia of chronic kidney disease. And as you referenced, it's been a busy year and we've read out Phase 3 data on two different programs: the dialysis program and the non
Akebia Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers